Correction to: Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits

Askar, Raad; Fredriksson, Elin; Manell, Elin; Hedeland, Mikael; Bondesson, Ulf; Bate, Simon T.; Olsén, Lena; Hedenqvist, Patricia

doi:10.1186/s12917-021-02858-1

Cited by 1 publication

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In veterinary medicine, the SC route for anaesthetic and analgesic adjuvants administration is mainly employed in feline and rabbit patients due to its practical convenience [ 20 – 22 ]. In other species, such as canine and equine, the use of the SC route is still controversial due to the pharmacokinetic behaviour mainly characterized by high intersubject variability which impredictably may result in clinical ineffectiveness [ 23 – 25 ].…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics of dexmedetomidine in anaesthetized horses following repeated subcutaneous administration and intravenous constant rate infusion

Di Cesare,

Rabbogliatti,

Draghi

et al. 2023

BMC Vet Res

View full text Add to dashboard Cite

Background The inclusion of dexmedetomidine (DEX) within a balanced general anaesthesia protocol is effective in improving the clinical outcome and recovery quality of anaesthesia in horses. This study aimed to determine the pharmacokinetic profile of DEX following repeated subcutaneous (SC) administration at 2 µg/kg every 60 min till the end of the procedure in comparison to intravenous constant rate infusion (CRI) at 1 µg/kg/h in anaesthetized horses undergoing diagnostic procedures up to the end of the diagnostic procedure. Results In the CRI and SC groups DEX maximum concentrations (Cmax) were 0.83 ± 0.27 ng/mL and 1.14 ± 0.71 ng/mL, respectively, reached at a time (Tmax) of 57.0 ± 13.4 min and 105.5 ± 29.9 min. Mean residence time to the last measurable concentration (MRTlast) was 11.7 ± 6.2 and 55.8 ± 19.7 min for the CRI group and SC groups, respectively. The apparent elimination half-life was 18.0 ± 10.0 min in the CRI group and 94.8 ± 69.8 min for the SC group, whereas the area under the curve (AUC0-last) resulted 67.7 ± 29.3 and 83.2 ± 60.5 min*ng/mL for CRI and SC group, respectively. Clearance was 16.26 ± 8.07 mL/min/kg for the CRI group. No signs of adverse effects were recorded in both groups. Conclusions The pharmacokinetic profile of DEX following repeated SC administration in anaesthetized horses was comparable to intravenous CRI administration during the intranaesthetic period and beneficial during the recovery phase from general anaesthesia. The SC route could be considered as an alternative to CRI for improving the recovery quality of equine patients undergoing general anaesthesia.

show abstract

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics of dexmedetomidine in anaesthetized horses following repeated subcutaneous administration and intravenous constant rate infusion

Di Cesare,

Rabbogliatti,

Draghi

et al. 2023

BMC Vet Res

View full text Add to dashboard Cite

show abstract

Correction to: Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits

Abstract: An amendment to this paper has been published and can be accessed via the original article.

Cited by 1 publication

References 1 publication

Pharmacokinetics of dexmedetomidine in anaesthetized horses following repeated subcutaneous administration and intravenous constant rate infusion

Pharmacokinetics of dexmedetomidine in anaesthetized horses following repeated subcutaneous administration and intravenous constant rate infusion

Contact Info

Product

Resources

About